Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL22092139

NCC(Cn1nc2cc(-c3ccc(C(F)(F)F)nc3)ccn2c1=O)=C(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 3/20 0.35
▸ GPR139 Q6DWJ6 7/20 0.34
▸ METAP2 P50579 2/20 0.33
▸ PIK3CD O00329 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ PIK3CB P42338 1/20 0.31
▸ PI4KA P42356 1/20 0.31
▸ PIK3CG P48736 1/20 0.31
▸ PI4KB Q9UBF8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22098775 0.95 MCHR1 (0.37) MCHR1GPR139METAP2PIK3CDPIK3CA
Trifluoroacetic Acid SCHEMBL22092166 0.87 GPR139 (0.34) GPR139
Trifluoroacetic Acid SCHEMBL22092031 0.86 FLT3 (0.38) GPR139
SCHEMBL22098836 0.81 MCHR1 (0.37) MCHR1GPR139METAP2PIK3CDPIK3CA
Trifluoroacetic Acid SCHEMBL22206411 0.81 GRM2 (0.38) GPR139
Hydrochloric Acid SCHEMBL22206407 0.81 MCHR1 (0.36) MCHR1GPR139METAP2PIK3CDPIK3CA
Trifluoroacetic Acid SCHEMBL22092044 0.81 CHRM1 (0.36) GPR139
Trifluoroacetic Acid SCHEMBL22092064 0.80 GPR139 (0.36) GPR139
SCHEMBL22092135 0.80 GRM2 (0.36) GPR139PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL30641024 0.80 GRM2 (0.36) GPR139PIK3CDPIK3CAPIK3CBPI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-11-21 — — US disclosed
US-20220024918-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2022-01-27 — — US disclosed
EP-3894408-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Yuhan Corporation (KR) 2021-10-20 — — EP disclosed
US-11091479-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2021-08-17 — — US disclosed
US-20200223844-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2020-07-16 — — US disclosed
WO-2020121263-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2020-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091479-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same VAPB, HDLBP, VAPA MCHR1 2869/4885GPR139 4033/4885METAP2 1250/4885
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same VAPB, HDLBP, VAPA MCHR1 2869/4885GPR139 4033/4885METAP2 1250/4885
US-20200223844-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME VAPB, HDLBP, VAPA MCHR1 2869/4885GPR139 4033/4885METAP2 1250/4885
US-20220024918-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME VAPB, HDLBP, VAPA MCHR1 2869/4885GPR139 4033/4885METAP2 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback